China Pharmaceutical Companies Seek Opportunities Overseas
This article was originally published in PharmAsia News
Executive Summary
Beijing Second Pharmaceutical, a subsidiary of Beijing Pharmaceutical Group, will collaborate with U.S.-based Frontage Laboratories to jointly develop 12 products for abbreviated new drug applications in the next five years. The new drugs will be marketed in China, the U.S. and European countries. In addition, Second Pharmaceutical has signed a strategic agreement with Poland's Adamed to cooperate on import and export registration, original equipment manufacturing and marketing. It is also working with an American pharmaceutical distributor to market these drugs internationally. Currently, more than 10 Chinese firms have received U.S. and EU cGMP authentication and applied for U.S. FDA approval of their drugs. These include Guangdong Oriental Sunshine Pharmaceuticals and Shanghai Sine Pharma Laboratory. Analysts observe that global demand of quality inexpensive generic drugs will give Chinese companies an edge. (Click here for more - Chinese Language)